1-3 of 3
Rebecca Tombleson, PharmD
Close
Sort by
Journal Articles

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

Ryan James Caddell, PharmD, Braydon Schaible, MPH, Zhenjun Ma, PhD, Elizabeth Dimaggio, PharmD, BCOP, Rebecca Tombleson, PharmD, BCOP, Claudio Anasetti, MD, Ernesto Ayala, MD, Brian C. Betts, MD, Mohamed A. Kharfan-Dabaja, MD, Frederick L. Locke, MD, Taiga Nishihori, MD, Joseph A. Pidala, MD, Hugo F. Fernandez, MD, Asmita Mishra, MD
Journal: Blood
Blood (2016) 128 (22): 3486.
https://doi.org/10.1182/blood.V128.22.3486.3486
Published: 2016
Journal Articles

Impact of Obesity in Patients with Multiple Myeloma Receiving High-Dose Melphalan Followed By Autologous Hematopoietic Cell Transplantation

Justina Ofori Frimpong, PharmD, BCOP, Rebecca Tombleson, PharmD, BCOP, Melissa Alsina, Jamie Shapiro, PharmD, BCOP, Jongphil Kim, PhD, Binglin Yue, MS, Janelle Perkins, PharmD, BCOP, Taiga Nishihori, MD
Journal: Blood
Blood (2016) 128 (22): 4636.
https://doi.org/10.1182/blood.V128.22.4636.4636
Published: 2016
Journal Articles

Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates,

Jamie Shapiro, PharmD, Janelle Perkins, PharmD, Ryan Bookout, PharmD, Rebecca Tombleson, PharmD, Ernesto Ayala, MD, William E. Janssen, PhD, Claudio Anasetti, MD, Hugo F. Fernandez, MD
Journal: Blood
Blood (2011) 118 (21): 4060.
https://doi.org/10.1182/blood.V118.21.4060.4060
Published: 2011